Document is current
Any future updates will be listed below
-
Authors
Jairath, Vipul https://orcid.org/0000-0001-8603-898X
Vuyyuru, Sudheer K
Zou, Guangyong
Ma, Christopher
Neustifter, Blue
Agboton, Christian
Romo Bautista, Itzel
Allocca, Mariangela https://orcid.org/0000-0002-7204-1739
An, Yoon-Kyo
Begun, Jakob https://orcid.org/0000-0001-5256-7672
Bryant, Robert V
Danese, Silvio
Dubinsky, Marla
Feagan, Brian G
Freire, Marcelo
Novak, Kerri L
Panaccione, Remo
Pudipeddi, Aviv
Rubin, David T
Sands, Bruce E
Sparrow, Miles P
Taylor, Stuart A
Gecse, Krisztina B
Wilkens, Rune
Maaser, Christian
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06257706 at ClinicalTrials.govnct01698307 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn’s disease: rationale, design and protocol for the randomised controlled VECTORS trial
https://doi.org/10.1136/bmjgast-2025-002088
Documents that mention this clinical trial
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
https://doi.org/10.1016/s0140-6736(15)00068-9
Evaluating treatment to a target of transmural healing in patients with moderately to severely active Crohn’s disease: rationale, design and protocol for the randomised controlled VECTORS trial
https://doi.org/10.1136/bmjgast-2025-002088
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals
- License Information
